Keyword: Turing Pharmaceuticals
News
20.11.2019
- Martin Shkreli, former CEO of the Retrophin hedge fund and Turing Pharmaceuticals, who was convicted of securities fraud and conspiracy in 2017, appears to have run out of options...
News
22.07.2019
- Martin Shkreli has lost his bid to overturn a seven-year prison sentence year for fraud and will remain incarcerated. The eccentric former CEO of Turing Pharmaceuticals – who...
News
15.07.2016
- A US federal judge has set Jun. 26, 2017 as the trial date for Martin Shkreli, the 33-year-old founder of Retrophin and Turing Pharmaceuticals and former CEO of KalaBios as well as...
News
21.03.2016
- The former general counsel of Turing Pharmaceuticals said on Thursday that he and other executives had repeatedly objected to a plan by Martin Shkreli, then chief executive, to...
News
09.02.2016
- Martin Shkreli, the 32-year-old former CEO of Turing Pharmaceuticals who made negative headlines last year after jacking up the price of the toxmoplasmosis drug Daraprim...
News
28.01.2016
- The pharmaceutical industry has often been accused of trying to keep affordable generic drugs off the market, with the addition – for example – of new indications or product...
News
05.01.2016
- Goldberg Law PC has announced a class action suit against KaloBios Pharmaceuticals, charging that the company, until recently headed by industry “bad boy” Martin Shkreli, may have...
News
22.12.2015
- Martin Shkreli, CEO of Turing Pharma, which made headlines by raising the price of the 62-year-old drug, Daraprim (pyrimethamine) from $13.50 to $700 a tablet shortly after...
